Nima J. Movahedi advises clients on a broad spectrum of complex corporate transactions, particularly in the aerospace & defense, technology, and life sciences sectors.
Nima leads boards and management with his extensive experience in complex financing and acquisition structures to guide private and public companies, venture capital and private equity firms, and investment banks on:
Mergers and acquisitions
Venture, growth capital, and private equity transactions
Structured equity, pre-IPO debt and equity financings, and similar private capital transactions
Public and private securities offerings and securities law compliance
Early-stage formation and corporate strategy
Employment matters and equity incentives
Restructuring and special situations
He helps corporate clients navigate challenges that arise on the path to exit, and leverages access to the full resources of Latham’s global platform to address key issues in sophisticated cross-border transactions.
Experience
Nima’s representative experience includes advising:
Mergers & Acquisitions
Icosavax on its US$1.1 billion sale to AstraZeneca
Skrewball on selling a majority stake to Pernod Ricard
Ouster on its US$400 million merger of equals with Velodyne Lidar
Virgin Orbit on its US$3.2 billion merger with NextGen Acquisition Corp. II
Offerpad on its US$3 billion merger with Supernova Partners Acquisition Company
Owlet on its US$1.4 billion merger with Sandbridge Acquisition Corp.
Latch on its US$1.6 billion merger with TS Innovation Acquisitions Corp.
Talkspace on its US$1.6 billion merger with Hudson Executive Investment Corp.
Ouster on its US$1.9 billion merger with Colonnade Acquisition Corp.
GCM Grosvenor on its US$2 billion merger with CF Finance Acquisition Corp.
Cryoport on its US$320 million acquisition of Chart Industries’ cryobiological products business
Virgin Galactic on its US$1.5 billion merger with Social Capital Hedosophia Holdings
The Committee of Independent Directors of T-Mobile US on its US$146 billion merger between T-Mobile US and Sprint
Impact Biomedicines on its up to US$7 billion sale to Celgene
PIMCO on acquiring Gurtin Municipal Bond Management
ICU Medical on its US$900 million acquisition of Pfizer’s Hospira Infusion Systems business
Breathe Technologies on its US$130 million sale to Hill-Rom
Mission Lane on acquiring LendUp’s credit cards business
Putney on its US$200 million sale to Dechra Pharmaceuticals
Venture, Growth Capital, and Private Equity
a16z
Eclipse Ventures
Goldman Sachs
Great Hill Partners
Invus
KKR
L Catterton
Lightspeed Venture Partners
Meritech Capital Partners
Novo Ventures
PIMCO
Virgin Investments
Emerging Companies
Aerospace & Defense / Mobility
Amphenol
Joby Aviation
Shield AI
Virgin Galatic
Virgin Hyperloop
Virgin Orbit
ZeroAvia
Technology
Advantage Data
Agrovision
Aspiration
Blueground
Bolt Threads
Care.com
Evergent
GrooveLabs
Higher Grounds Education
Latch
LogMeIn
Mosaic Building Group
Newlight
Offerpad
Omio
Ouster
Owlet
Syntiant
Talkspace
Truepill
X-energy
Life Sciences
AcuFocus
Alcresta
Ambry Genetics
Cercacor
Equinox Ophthalmic
Hart
Immunis
Impact Biomedicines
Invoy
Mineralys
Regeneration Biomedical
Relievant Medsystems
Saluda
SQZ Biotechnologies
10x Health
Retail
Beauty Health
Incipio
Skrewball
Qualifications
Bar Qualification
California
Education
JD, Boston University School of Law cum laude
BA, University of California, Los Angeles Dean's List
Firm honored by Law360 for advising startups, financial institutions, VCs, digital asset and Web3 participants, and corporations on their most innovative and complex transactions, investigations, litigation, and regulatory matters.
Multidisciplinary team represented Sixth Street in the growth financing for the rail logistics systems provider in connection with a transformative acquisition in the rail fleet logistics industry.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.